The BioHub - by Avetix

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.I’m joined by Gerardo Ubaghs, CFO of Frontier Medicines. Gerardo has had one of the most unique career journeys you’ll hear — from being a professional violinist, to working in investment banking, and then stepping into biotech where he’s helped build and finance some of the most innovative companies out there. At Frontier, he’s driving strategy and finance for their mission to unlock previously undruggable targets using chemoproteomics and AI to develop precision medicines.Enjoy and stay tuned.

Welcome back to another episode of The Bio Hub, we were delighted to be joined by two leaders from Shinobi Therapeutics, a company pushing the boundaries of off-the-shelf cell therapy through an innovative stealth cell platform that aims to overcome immune rejection and unlock the full potential of allogeneic CAR-T and CAR-NK therapies."With us is Dr. Dan Kemp, CEO of Shinobi Therapeutics. Dan brings over two decades of experience at the intersection of science and business in the cell and gene therapy space. He earned his PhD in molecular pharmacology from the University of Kent, completed postdoctoral work at Massachusetts General Hospital, and held an HHMI fellowship at Harvard Medical School. His industry leadership spans major roles at Takeda, where he helped shape the company’s cell therapy strategy, and as CEO of Wugen, where he advanced off-the-shelf NK and CAR-T therapies through key stages of developmentAlso with us is Dr Steven Katz, a medical oncologist and physician-scientist with a long-standing focus on immuno-oncology and cellular therapies. Before joining Shinobi, Dr. Katz held leadership roles guiding early clinical development and translational strategy at TriSalus Life Sciences. His work has consistently centered on designing and executing clinical trials that bring advanced therapies—especially cell-based treatments—closer to patients. Now at Shinobi, he plays a critical role in shaping the company’s clinical vision, steering development programs for immune-evasive, off-the-shelf cell therapies, and leading efforts to move first-in-class products into the clinic.

From BIO Boston: Alex Blyth, CEO of LifT BiosciencesIn this powerful opening episode from BIO 2025, I sit down with Alex Blyth, the founder and CEO of LifT Biosciences — a company re-engineering the immune system to finally beat cancer at its own game.We talk about:Why targeted therapies are failing most patientsWhat tumour escape is and why it’s the real enemyHow LiFt’s “super neutrophils” could be the Keytruda of innate immunityAnd the personal loss that pushed Alex to rethink everything we know about cancer treatmentAlex’s story is sharp, ambitious, and deeply personal — exactly the kind of leadership biotech needs right now.This is the first in a series of in-person interviews from BIO Boston with some of the sharpest founders and execs in the industry. Stay tuned — more to come.

Welcome to another episode of The Bio Hub. We were thrilled to welcome Jaideep Dudani, Founding CEO of Ouro Medicines and Portfolio Principal at Monograph Capital. Jaideep holds a PhD from MIT and a BS in Bioengineering from UCLA. Jaideep began his career at Vida Ventures and played key R&D, strategy, and business development roles at Relay Therapeutics. Jaideep later helped launch Human Immunology Biosciences (HI Bio), leading portfolio development and strategic initiatives prior to its acquisition by Biogen.In early 2025, he co founded Ouro Medicines—backed by Monograph, GSK, NEA, TPG, Norwest, and others to pull of an incredible $120M Series A, to pioneer ‘immune reset’ T cell engager therapies targeting B cell mediated autoimmune and inflammatory diseases. We’ll explore Jaideep's journey from bioengineering research to biotech entrepreneurship, as well as the promising data from Ouro Medicines as well as Jaideep’s experience with building biotechs out from the ground up.

So welcome back to another episode of the Bio Hub, we were delighted to welcome Alec Ford (CEO of Karius) and Stacy Solorio (Chief people Officer at Karius). Alec is a veteran of the genomics and biotech industries with over 30 years of leadership experience. Alec is leading the charge in transforming infectious disease diagnostics through Karius’s groundbreaking liquid biopsy test, which uses microbial cell-free DNA and AI to detect over 1,000 pathogens from a single blood draw. Before joining Karius, Alec served as COO at Myriad Genetics, where he scaled diagnostics across oncology, women’s health, and prenatal care, and held senior roles at Pfizer, Novartis, Sanofi, and Nektar. His leadership is deeply informed by personal experience—his family’s encounter with severe infections underscored the critical need for faster, more precise diagnostics.Stacy Solorio is the Chief People officer at Karius. Stacy is a strategic people leader with deep expertise in building culture and scaling teams within fast-growing biotech organizations. She’s also the founder of Biocom’s HR Biotech Group and Executive HR Education program, and serves on the board of the Biocom California Institute. At Karius, she’s helping align talent initiatives with the company’s mission to bring cutting-edge diagnostics into clinical practice.

We were delighted to welcome Dr. Dan Williams, CEO and co-founder of SynaptixBio, a pioneering biotech company on a mission to develop life-changing treatments for children affected by devastating brain disorders, onto the bio hub. With over two decades of experience in the biotech and pharmaceutical industries, Dan has led teams from the lab bench to global clinical programs, and now he’s tackling one of the rarest and most challenging neurological diseases: TUBB4A-related leukodystrophies, including the severe H-ABC form.Under Dan’s leadership, SynaptixBio is leveraging cutting-edge antisense oligonucleotide (ASO) technology to silence disease-causing genes and bring hope to families with no existing treatment options. In just a few years, his team has secured orphan drug designations, raised significant funding, and is driving toward clinical trials with an urgency that reflects the needs of the patients they serve.We’ll talk to Dan about his journey from scientist to biotech CEO, the science behind SynaptixBio’s approach, and what it takes to bring a rare disease therapy from concept to clinic.

We were delighted to welcome Adam Thomas, Chief People & Experience Officer at MOMA Therapeutics onto the Bio Hub, where he brings over two decades of strategic HR leadership across the biotech, pharmaceutical, and consumer industries. Since joining MOMA in 2024, Adam has led the company’s people and culture strategy during its pivotal transition into a clinical-stage organization, focusing on creating a world-class employee experience that integrates physical, digital, and cultural environments. Prior to MOMA, he served as Chief People Officer and Corporate Secretary at Synlogic, Inc., where he guided HR and talent strategy through the company’s growth from pre-clinical to Phase III development. He also held senior HR leadership roles at Shire Pharmaceuticals, where he oversaw HR for Research & Development during a major expansion, and at SC Johnson, leading HR for Research, Development & Engineering with an emphasis on talent development and organizational effectiveness. Earlier in his career, Adam spent over a decade at Pfizer in a variety of HR leadership roles and held advisory and research roles at Gartner (formerly CEB) and Brann Worldwide. He holds an LL.B. in Law from the University of Edinburgh, an M.A. in Human Resource Management from the University of the West of England, and an M.B.A. from Boston University

From BIO Boston: Eamonn Hobbs, CEO of SyncromuneEamonn Hobbs is a biotech veteran and serial CEO — and in this episode, he shares how Syncromune is rewriting the playbook for immunotherapy.We talk about:– How Syncromune’s SYNC-T platform delivered 87% ORR and 53% CR in mCRPC– What it means to synchronize drug, device, and immune response– Raising one of the few $100M Series A rounds in 2024– The mindset needed to build and win in today’s brutal marketEamonn’s clarity, experience, and grit shine through — this is a must-listen for anyone building in biotech.More BIO Boston episodes dropping soon.

From BIO Boston: Spike Lo, VP of Business Development at AP BiosciencesIn this episode, I sit down with Spike Lo — a seasoned BD leader helping take AP Biosciences global.We dive into:— The rise of AP and their $96M raised to date— How their CD137-based T-cell engager platform is built for safety and precision— What sets Taiwan’s biotech ecosystem apart— Spike’s mindset on resilience, urgency, and global partnershipsA sharp conversation on building cross-border biotech with bold ambition.This episode is part of our in-person series from BIO 2025 — more to come.

Josh Mandel-Brehm, CEO of CAMP4 TherapeuticsIn this episode, I sit down with Josh Mandel-Brehm, the CEO of CAMP4 — a company pioneering a completely new approach in RNA therapeutics: upregulating gene expression using antisense oligonucleotides (ASOs).Josh shares the journey from a 5-person team to a publicly traded company, and how CAMP4’s platform is unlocking treatment for diseases previously out of reach — particularly in rare genetic and CNS disorders.We dive into:— What makes CAMP4’s approach so different— How they’ve scaled in a challenging market— The transition from private to public— Building culture through rapid growth— What’s coming next in Syngap, urea cycle disorders, and moreJosh is sharp, mission-driven, and speaks with clarity on how to build a resilient biotech from the ground up.This is one for anyone building bold platforms in biotech.